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DNA methylation is an epigenetic mechanism of reversible gene regulation 
which typically results in gene silencing upon hypermethylation in high CpG density 
regions of promoters (termed CpG islands), and increased gene expression when 
methylation occurs in gene bodies. Prior information on OA-associated changes in 
DNA methylation are limited to important single gene analyses and two studies on 
genome wide changes in cartilage and subchondral bone. Rushton et al present 
elegant work characterizing the genome-wide DNA methylation profile in articular 
cartilage from normal and OA-affected hip and OA-affected human knee joints. Results 
show that normal and OA hip cartilage have a unique methylation profiles, with 5322 
differentially methylated loci (DMLs) identified between both groups. They also show 
that OA hip and knee samples can be separated into two clusters based on their 
methylation profile. In total 15239 DMLs were identified between the two hip OA 
clusters, with an enrichment of genes involved in inflammation and immunity. The 
identification and isolation of subgroups with different methylation profiles may also be 
critical for the development of effective disease prevention and treatment, and to 





Osteoarthritis (OA) pathogenesis involves cartilage degradation, synovial 
inflammation, subchondral bone sclerosis, degeneration of ligaments and meniscus, 
and hypertrophy of the joint capsule. There can also be changes in periarticular 
muscles, nerves, bursa, and local fat pads that may contribute to OA. The 
manifestation of pathological changes in all joint tissues define OA as a disease of the 
‘whole’ joint, as an organ, resulting in organ dysfunction or joint failure (1). OA is a 
multifactorial disease in which gender, age, obesity and environment play a main role. 
OA has also a strong genetic component (2), however numerous studies failed to 
replicate genes, at GWAS significance level (5.10-8), with a full susceptibility to the 
disease. It has been proposed that this could be due to low penetrance polymorphisms 
in the population. Alternatively, it has been also proposed that this could, at least in 
part, be accounted for by inheritance of epigenetic modifications (3). 
 Epigenetics is defined as heritable changes in gene expression without changes 
in the DNA sequence. The term “heritable” refers to changes mainly between cell 
divisions and, sometimes, between generations; though in mammals the 
transgenerational inheritance is limited because germ cells, which give rise to the 
gametes, reset their epigenome prior to their reprogramming to a totipotent state (4). 
There are three main mechanisms involved in epigenetic regulation: i) post-
transcriptional modification of histones, that alters chromatin conformation and thus the 
accessibility to the transcriptional machinery; ii) non-coding RNAs (i.e. microRNAs), 
acting post-transcriptionally in the regulation of gene expression through binding to 
target mRNAs, and iii) DNA methylation. DNA methylation is the best characterized 
epigenetic mechanism and consists of the addition of a methyl group (CH3) from the 
methyl donor S-adenosylmethionine  (SAM) to a cytosine that is 5´ to guanine (CpG 
sites) to form methylated cytosine (5mC). This reaction is catalyzed by a family of 
enzymes called DNA methyltransferases (DNMTs). The major outcome of DNA 
methylation is gene silencing when this process takes place in high CpG density 
regions of promoters (termed CpG islands); in contrast, when methylation occurs in 
gene bodies it leads to increased gene expression, probably to prevent incorrect 
transcriptional initiation (5). Most tissue-specific methylation occurs at regions of lower 
CpG density close to CpG islands (termed CpG shores) and correlates with 
transcriptional repression of the corresponding gene (3). 
It has been proposed that epigenetics is involved in the phenotypic modulation 
that articular chondrocytes undergo during OA, generating these “altered” 
chondrocytes that overexpress cartilage-degrading proteases (collagenases and 
aggrecanases) and inflammatory mediators, therefore breaking the homeostatic 
balance toward extracellular matrix (ECM) degradation and probably playing a decisive 
role in the progression of the disease (6, 7). In this context, there have been several 
candidate-gene based studies investigating the role of DNA methylation in OA 
including growth differentiation factor-5 (GDF-5), manganese superoxide dismutase 
(MnSOD), interleukin-1 beta (IL-1β) and several matrix-degrading proteinases (MMP-3, 
MMP-9, MMP-13, MMP-14 and ADAMTS-4). Moreover, a work by de Andrés et al (8) 
demonstrated a novel mechanism for inflammatory gene regulation in OA 
chondrocytes, the demethylation of an enhancer that allows the binding of NF-ƙβ to 
facilitate the transcription of inducible nitric oxide synthase (iNOS).  
All of these prior studies on DNA methylation focused on a single or a small 
number of genes. In this issue of Arthritis & Rheumatology, Rushton et al present  
elegant work characterizing the genome-wide DNA methylation profile of normal and 
hip cartilage and knee cartilage (9). This study shows that normal and OA hip cartilage 
have a unique methylation profile, with 5322 differentially methylated loci (DMLs) 
identified between both groups. They also show that OA hip samples can be separated 
into two clusters based on their methylation profile. In total 15239 DMLs were identified 
between the two clusters, with an enrichment of genes involved in inflammation and 
immunity. These results confirm previous findings by our group in which two clusters of 
knee OA patients, with enrichment of similar genes involved in inflammation and 
immunity, had also been described (10). These two studies support the existence of an 
inflammatory OA phenotype and strengthen the consideration that, at least, part of the 
pathogenesis of OA can be attributable to epigenetics and that analysis of DNA 
methylomes may help to understand the complex molecular basis of this 
heterogeneous disease. 
The study published in this issue of Arthritis & Rheumatology also shows that 
cartilage DNA methylome is able to distinguish joint-specific OA. A comparison 
between hip OA and knee OA revealed 5547 DMLs between these two groups, 
including DMLs in several genes known to be involved in OA pathogenesis such as 
ADAM12, ADAMTS5, CHST11, GDF5 or MCF2L. These findings confirm that hip and 
knee OA are two diseases that share some common pathogenesis pathways but also 
with clear differences between them.   
The role played by DNA methylation in OA is beginning to be investigated and 
the study by Rushton et al makes an important contribution in this respect. However, 
further efforts should be directed to address additional important and unresolved 
issues. The DNA methylome of other OA joint tissues such as synovial membrane and 
subchondral bone needs to be characterized. Information in this regard is limited to a 
recent genome-wide DNA methylation study which showed differential methylated 
regions between osteoporotic and OA bone (11). Interestingly, these regions were 
enriched in genes associated with cell differentiation and skeletal embryogenesis, such 
as those in the homeobox superfamily. These results are very interesting because 
similar results involving the homeobox superfamily were found in both genome-wide 
DNA methylation studies performed in OA cartilage (9,10). Furthermore, joint 
morphology is a very relevant risk factor for OA development and progression. In-depth 
analysis of these results could help understand the connection between joint 
morphology and OA. 
Another important point to investigate is whether and how inflammatory stimuli 
are able to induce changes in the methylation pattern of OA (and vice-versa). In this 
sense, many proteinases are highly induced by inflammatory cues such as cytokines; 
in line with this, the two main pro-inflammatory cytokines involved in OA, IL-1β and 
TNF-α, are able to induce changes in the methylation pattern of specific genes (12). A 
very recent study suggested a role for 5-hydroxymethylcytosines (5hmC) in OA as 
inflammatory cytokines (IL-1β, TNF-α and Oncostatin M) modulate the expression of 
TET1 (one of the enzymes that converts 5mC to 5hmC) in OA chondrocytes. Increased 
TET expression led to an enrichment of 5hmC in CpG sites of gene bodies and 
promoters of some OA-related genes such as MMP-1, -3 and -13, thereby increasing 
their expression in OA (13). 
Epigenetic factors, including DNA methylation, histone modifications, and 
microRNAs may play central roles in controlling changes in gene expression and 
genomic instability during aging (14); aging and age-related diseases are generally 
characterized on the one hand by genome-wide hypomethylation, leading to genomic 
instability and inefficient gene repression, and on the other hand by promoter-specific 
hypermethylation, that leads to loss of expression control and inappropriate silencing 
(15,16). The understanding of the specific mechanisms as well as the different 
pathways involved in the epigenetic modifications underlying aging and/or OA is 
another major focus of research that it is necessary to explore. 
DNA methylation and mitochondrial dysfunction is another interesting topic. 
Mitochondria play a role in the pathogenesis of OA (17) and mitochondria and the 
mitochondrial genome modulate the nuclear epigenome (18). In line with this, carriers 
of the mitochondrial DNA (mtDNA) haplogroup J show increased levels of global DNA 
methylation when compared with other mtDNA variants (19). Consistently, cybrids from 
this haplogroup also show higher methylation levels than cybrids containing other 
mtDNA haplogroups (19); carriers of this haplogroup also show different DNA 
methylation patterns  than carriers of the most common haplogroup H, mainly in genes 
related to inflammation and apoptosis (personal data). Further, Kelly et al found that 
mouse embryonic stem cells containing different mtDNA haplogroups on a uniform 
nuclear background were associated with different gene expression and DNA 
methylation profiles (20). Conceivably, mitochondrial reactive oxygen species (ROS) 
production, which differs among the mtDNA haplogroups (21), represents an important 
retrograde signaling stimulus for nuclear epigenomic DNA modifications (22). The 
emergence of the mitochondrial genome as one of the regulators of the nuclear DNA 
function is a very important issue and should also be studied in detail. 
Metabolic alterations such as type 2 diabetes mellitus and obesity are 
consistently associated with OA suggesting the existence of a metabolic phenotype of 
OA (23). Moreover, there is evidence that obese and diabetic patients show different 
epigenetic marks than non-obese and non-diabetic individuals (24). Altogether, these 
data indicate that metabolic alterations modify the DNA methylome suggesting an 
interesting connection between methylation and the newly defined metabolic 
phenotype of OA.  
Dietary changes are also able to induce changes on the DNA methylome since 
SAM, the main methyl donor, is acquired through the intake of folic acid and vitamins 
B6 and B12, therefore, a decrease in the uptake of these dietary supplements could 
lead to a global hypomethylation status. In a recent article, Barua et al demonstrated 
that the offspring of pregnant mice fed a diet high in folic acid exhibit significant 
changes in DNA methylation patterns of their neuronal tissue (25). In the context of OA, 
some studies even propose the use of SAM as an effective complementary medicine 
(26), although its effectiveness has not been conclusively proven. Improved clinical 
trials must be carried out regarding to the intake of methyl donors and also to explore 
its potential mechanisms of action such as changes in DNA methylation and associated 
reduction of inflammatory mediators and cartilage-degrading proteinases. 
Methylation is a dynamic process prone to changes in the environment. For this 
reason, in-depth studies are necessary to determine if the methylation changes that 
take place in OA are cause or consequence of the changes produced by the disease 
itself, or even a combination of both scenarios. In this sense, studies involving the 
analysis of DNA methylation changes in in vitro models of chondrogenesis could be 
useful. Chondrogenesis has been revealed as a process involved in OA pathogenesis 
and it has been proposed that defective chondrogenesis could be responsible for 
defects in cartilage repair contributing to OA (27). Work by Ezura et al (28) described 
low DNA methylation levels of CpG-rich promoters of genes regulating 
chondrogenesis, including SOX9 or RUNX2, in human synovium-derived mesenchimal 
stem cells. Interestingly, low methylation levels in CpG promoter for RUNX2 in OA 
chondrocytes were also detected in both studies by Rushton et al (9) and Fernández-
Tajes et al (10). Together, these data indicate that changes in the methylation patterns 
of cells with chondrogenic capacity occur and should also be the focus of future 
studies. 
In conclusion, the study by Rushton et al strengthens the role of DNA 
methylation in OA and makes a call to research community to increase the efforts on 
the role played by epigenetics in the development of OA. In regard to therapeutic 
implications, the characterization and analysis of cartilage DNA methylomes offers not 
only potential therapeutic targets for the treatment of OA, but also enables the design 
of a map of epigenetic marks that can help develop potential biomarkers for diagnosis, 
prognosis, drug-response, chondrogenesis or homeostasis from high-resolution 
screening technologies, as proposed for other diseases (29). The identification and 
isolation of subgroups with different methylation profiles may also be critical for the 
development of effective treatment and disease prevention. Answering the question in 
the title of this editorial, it is time for epigenetics in OA, time to elucidate the role of 
epigenetics to characterize the different OA phenotypes (Figure 1) such as 
inflammatory, aging and metabolic-related. 
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